[go: up one dir, main page]

LT1781787T - Akių sutrikimų, charakterizuojamų padidintu vidiniu akispūdžiu, gydymas sirnr pagalba - Google Patents

Akių sutrikimų, charakterizuojamų padidintu vidiniu akispūdžiu, gydymas sirnr pagalba

Info

Publication number
LT1781787T
LT1781787T LTEP05781264.6T LT05781264T LT1781787T LT 1781787 T LT1781787 T LT 1781787T LT 05781264 T LT05781264 T LT 05781264T LT 1781787 T LT1781787 T LT 1781787T
Authority
LT
Lithuania
Prior art keywords
sirnas
treatment
intraocular pressure
disorders characterized
eye disorders
Prior art date
Application number
LTEP05781264.6T
Other languages
English (en)
Inventor
Ana I. Jimenez
Angela Sesto
José P. Roman
Irene Gascon
Gonzalo Gonzalez De Buitrago
Original Assignee
Sylentis S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35967904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT1781787(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0418762.1A external-priority patent/GB0418762D0/en
Priority claimed from GB0503412A external-priority patent/GB0503412D0/en
Application filed by Sylentis S.A.U. filed Critical Sylentis S.A.U.
Publication of LT1781787T publication Critical patent/LT1781787T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
LTEP05781264.6T 2004-08-23 2005-08-23 Akių sutrikimų, charakterizuojamų padidintu vidiniu akispūdžiu, gydymas sirnr pagalba LT1781787T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0418762.1A GB0418762D0 (en) 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma
GB0503412A GB0503412D0 (en) 2005-02-18 2005-02-18 Methods and compositions to treat glaucoma
PCT/GB2005/050134 WO2006021817A2 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated introacular pressure by sirnas

Publications (1)

Publication Number Publication Date
LT1781787T true LT1781787T (lt) 2017-07-25

Family

ID=35967904

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP05781264.6T LT1781787T (lt) 2004-08-23 2005-08-23 Akių sutrikimų, charakterizuojamų padidintu vidiniu akispūdžiu, gydymas sirnr pagalba

Country Status (17)

Country Link
US (11) US8030284B2 (lt)
EP (3) EP1781787B1 (lt)
JP (2) JP5766900B2 (lt)
CN (2) CN102895673A (lt)
AU (1) AU2005276245C1 (lt)
CA (1) CA2578064C (lt)
CY (1) CY1119061T1 (lt)
DK (1) DK1781787T3 (lt)
ES (1) ES2632913T3 (lt)
HR (1) HRP20171010T8 (lt)
HU (1) HUE033977T2 (lt)
LT (1) LT1781787T (lt)
PL (1) PL1781787T3 (lt)
PT (1) PT1781787T (lt)
RU (1) RU2407531C2 (lt)
SI (1) SI1781787T1 (lt)
WO (1) WO2006021817A2 (lt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
SI1781787T1 (sl) 2004-08-23 2017-08-31 Sylentis S.A.U. Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US8673873B1 (en) * 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
EP1976986A2 (en) * 2005-12-30 2008-10-08 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
EP1977246B1 (en) * 2005-12-30 2010-01-20 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CN101583714A (zh) * 2006-11-09 2009-11-18 优尼拜尔斯金股份有限公司 增殖性疾病治疗中钠-钾ATP酶α1或α3亚单位的靶向作用
US20100009920A1 (en) 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
TW200920406A (en) 2007-08-24 2009-05-16 Oncotherapy Science Inc EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis
BRPI0816150A2 (pt) 2007-08-24 2019-09-24 Oncotherapy Science Inc genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
CA2794187C (en) 2010-03-24 2020-07-14 Rxi Pharmaceuticals Corporation Rna interference in ocular indications
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
JP6157354B2 (ja) 2010-11-10 2017-07-05 ナイジェル， エル． ウェブ， ヌクリオン（Ｎｕｃｌｉｏｎｓ）及びリボキャプシド（ｒｉｂｏｃａｐｓｉｄｓ）
RU2460517C1 (ru) * 2011-07-14 2012-09-10 Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
KR102120060B1 (ko) * 2012-09-05 2020-06-09 실렌티스 에스.에이.유. 눈 컨디션의 치료 및/또는 예방을 위한 조성물 및 방법에 있어서 siRNA 및 이의 용도
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US8908303B1 (en) 2013-07-30 2014-12-09 Kabushiki Kaisha Toshiba Method for servo demodulation and disk storage apparatus
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
CN106068324B (zh) 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015132303A1 (en) * 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CA2947619A1 (en) * 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
FR3031503A1 (fr) * 2015-01-14 2016-07-15 Qualipac Sa Recipient, composant de recipient, et gamme de tels produits
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
CA3009769C (en) * 2015-12-29 2021-01-12 National University Corporation Hokkaido University Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof
US10799676B2 (en) 2016-03-21 2020-10-13 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
CN106267222B (zh) * 2016-09-12 2020-05-19 北京市心肺血管疾病研究所 血管紧张素ⅱ用于改善大分子药物或药物载体的心脏递送
CN106228753A (zh) * 2016-09-30 2016-12-14 福建工程学院 一种意外摔倒监控方法、系统及终端
EP4389894A3 (en) * 2017-03-10 2024-08-28 The Medical College of Wisconsin, Inc. Riboswitch modulated gene therapy for retinal diseases
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
TWI851574B (zh) * 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
WO2020112164A1 (en) * 2018-11-29 2020-06-04 Ojai Retinal Technology, Llc Process for safely providing retinal phototherapy based on determination of rpe melanin levels
IL284700B2 (en) * 2019-01-23 2025-10-01 Regeneron Pharma Treating eye conditions with angiopoietin-like 7 inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP4110465A4 (en) * 2020-02-24 2024-06-12 The Board Of Regents Of The University Of Texas System MOLECULAR BIOMARKERS AND TARGETS FOR FUCHS ENDOTHELIAL CORNEAL DYSTROPHY AND GLAUCOMA
WO2021206917A1 (en) * 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
CA3210480A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
WO2022251629A2 (en) * 2021-05-27 2022-12-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing carbonic anhydrase 2 expression
WO2024145473A1 (en) * 2022-12-30 2024-07-04 Salk Institute For Biological Studies Manipulation of adrenergic receptors to influence immune cell differentiation and function
EP4562158A1 (en) 2023-06-13 2025-06-04 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
MXPA04010282A (es) * 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
BR0309623A (pt) 2002-04-30 2005-02-09 Alcon Inc Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040115815A1 (en) 2002-07-24 2004-06-17 Immusol, Inc. Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker
US20040146858A1 (en) 2002-07-24 2004-07-29 Immusol, Inc. Novel siRNA gene libraries and methods for their production and use
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
KR20050083855A (ko) * 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
DE10322662A1 (de) * 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
CN1498964A (zh) 2002-11-07 2004-05-26 本元正阳基因技术股份有限公司 可诱导RNAi途径的用于基因治疗的系列重组腺相关病毒
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050197364A1 (en) 2003-10-07 2005-09-08 Kelly Michael G. Amide compounds as ion channel ligands and uses thereof
GB0324334D0 (en) 2003-10-17 2003-11-19 Pilkington Plc Load bearing laminates
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
CA2555335A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
SI1781787T1 (sl) 2004-08-23 2017-08-31 Sylentis S.A.U. Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna
GB0421169D0 (en) 2004-09-23 2004-10-27 Securis Ltd Apparatus and process for the printing of microstructures
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
CA2598234A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US7621431B2 (en) * 2005-04-06 2009-11-24 Chicco Usa, Inc. Folding stroller tray
KR101283539B1 (ko) * 2007-08-29 2013-07-15 삼성전자주식회사 역전 구조의 비휘발성 메모리 소자, 그 스택 모듈 및 그제조 방법

Also Published As

Publication number Publication date
SI1781787T1 (sl) 2017-08-31
US20140018527A1 (en) 2014-01-16
CA2578064C (en) 2015-10-13
US20100022623A1 (en) 2010-01-28
US7592325B2 (en) 2009-09-22
AU2005276245A1 (en) 2006-03-02
PT1781787T (pt) 2017-07-17
RU2007110646A (ru) 2008-09-27
EP1781787A2 (en) 2007-05-09
WO2006021817A3 (en) 2006-06-08
ES2632913T3 (es) 2017-09-18
US8252759B2 (en) 2012-08-28
CA2578064A1 (en) 2006-03-02
JP5766900B2 (ja) 2015-08-19
US20090099111A1 (en) 2009-04-16
US8030284B2 (en) 2011-10-04
WO2006021817A2 (en) 2006-03-02
EP2292757A3 (en) 2011-11-16
US8258110B2 (en) 2012-09-04
US8247387B2 (en) 2012-08-21
JP2008510786A (ja) 2008-04-10
RU2407531C2 (ru) 2010-12-27
US20090105175A1 (en) 2009-04-23
AU2005276245C1 (en) 2015-02-26
HRP20171010T8 (hr) 2017-11-03
CN102895673A (zh) 2013-01-30
EP2298892A3 (en) 2011-11-16
AU2005276245B2 (en) 2010-06-03
US20090105176A1 (en) 2009-04-23
US20090099113A1 (en) 2009-04-16
US8389490B2 (en) 2013-03-05
US8247386B2 (en) 2012-08-21
JP2012205594A (ja) 2012-10-25
US20090099112A1 (en) 2009-04-16
DK1781787T3 (en) 2017-07-31
US8252758B2 (en) 2012-08-28
PL1781787T3 (pl) 2018-01-31
EP1781787B1 (en) 2017-04-12
US8198250B2 (en) 2012-06-12
US7902169B2 (en) 2011-03-08
US20090099114A1 (en) 2009-04-16
EP2298892A2 (en) 2011-03-23
HRP20171010T1 (hr) 2017-09-22
CY1119061T1 (el) 2018-01-10
US20070270365A1 (en) 2007-11-22
EP2292757A2 (en) 2011-03-09
CN105251024A (zh) 2016-01-20
US8951982B2 (en) 2015-02-10
HUE033977T2 (en) 2018-02-28
US20100331394A1 (en) 2010-12-30
US20060234970A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
HRP20171010T1 (hr) Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
ZA200704932B (en) Rnai inhibition of CTGF for treatment of ocular disorders
IL196413A0 (en) Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
EP2059282A4 (en) APPARATUS, METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISORDERS
PL383268A1 (pl) Kompozycje oftalmiczne i sposoby leczenia oczu
IL200528A0 (en) Methods of treating ophthalmic diseases
LT2444079T (lt) Kompozicijos ir būdai, skirti akių sutrikimų gydymui
EP1933751A4 (en) INTRASTROMAL REFRACTIVE SURGERY BY INDUCTION OF SHAPE CHANGES IN THE HORN SKIN
EG24420A (en) Treatment of ophthalmic conditions
IL209948A0 (en) Method of eye treatment for prevention of presbyopia and glaucoma, and means for carrying out said treatment
PT2056863T (pt) Tratamento de doenças oculares
EP2083841A4 (en) TREATMENT OF MACULAR DEGENERATION FROM AGING AND OTHER OCULAR DISEASES
EP2296682B8 (en) Methods of treating ophthalmic disorders
GB0414772D0 (en) Ophthalmic eye preparation
ZA200806881B (en) Therapeutic prophylactic ophthalmologic lens for pseudo-aphakic eyes and/or eyes suffering neurodegeneration
WO2011003103A3 (en) Pharmacology of visual cycle modulators
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1895849A4 (en) METHODS FOR TREATING OCULAR DISEASES INDUCED BY BETA-AMYLOID PROTEINS
ZA200807828B (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
GB2433322B (en) Statistical control of adaptive ocular filter stability
GB0523964D0 (en) The treatment of ophthalmic diseases
SI2155733T1 (sl) Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka
HK1129330A (en) Methods of inhibiting the distortions that occur during the production of silicone hydrogel ophthalmic lenses
HK1108112A (en) Rnai inhibition of ctgf for treatment of ocular disorders
IL208831A0 (en) Methods of treating ophthalmic disorders